ANTIDIABETIC ACTIVITY OF NIGELLA SATIVA L. SEED POWDER AND ITS COMBINATION WITH GLICLAZIDE IN ALLOXAN INDUCED DIABETIC MICE
Objective: In Indonesia, Nigella sativa (NS) has been widely used for the treatment of diabetes mellitus. The aim of this study was to evaluate the antidiabetic activity of its seed powder and its combination with gliclazide.
Methods: NS was used in seed powder suspension form. At study's begin, Oral Glucose Tolerance Test (OGTT) was performed. And then the mice were induced with 60 mg/kg alloxan intravenously and were treated with 1300 mg/kg NS (NS1), 2000 mg/kg NS (NS2), 0,65 mg/kg gliclazide, and combination of NS1-gliclazide that administered orally for 3 weeks. NS1 was also administered daily to mice induced high-fat emulsion for 3 weeks.
Results: The results showed that in OGTT, NS1 and NS2 inhibit the elevation of plasma glucose level after administering glucose. In mice induced alloxan, plasma glucose level in both NS1 and NS2 was significantly lower than diabetic control and gliclazide group. And NS2 showed more significantly less damage in Langerhans than the other groups. The combination did not showed a better effect than the single use. In mice induced high-fat emulsion, NSI improved the sensitivity of insulin by increasing KITT.
Conclusion: The results suggest that NS has an antidiabetic activity by increasing insulin production and improving sensitivity of insulin. The combination NS with gliclazide was probably antagonism.
2. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes. Diabetes Care 2004;27:1047-53.
3. Sumana G, Suryawashi SA. Effect of Vinca rosea extracts in treatment of alloxan diabetes in male albino rats. Indian J Exp Biol 2001;39:748-59.
4. Holman RR, Turne RC. Oral Agents and Insulin in the Treatment of NIDDM. In: Pickup J, William G, editors. Text Book of Diabetes. UK: Blackwell; 1991. p. 467-9.
5. Rao BK, Kesavulu MM, Apparao C. Antihyperglycemic activity of Momordica cymbalaria in alloxan diabetic rats. J Ethnopharmacol 2001;78:67-71.
6. Aisyah N, Sudiro I, Sukrasno. Minorthesis: Telaah Fitokimia Biji Jinten Hitam Pahit (Nigella sativa Linn., Ranunculaceae). Bandung: Institut Teknologi Bandung; 1995.
7. Sharma NK, Ahirwar D, Jhade D, Gupta S. Medicinal and phamacological potential of nigella sativa: a review. Ethnobotanical Rev 2009;13:946â€“55.
8. Meddah B, Robert D, Moulay. Nigella sativa inhibits intestinal glucose absorption and improves glucose tolerance in rats. J Ethnopharmacol 2009;121:419-24.
9. Kanter M, Akpolat M, Aktas C. Protective effects of the volatile oil of nigella sativa seeds on b-cell damage in streptozotocin-induced diabetic rats: a light and electron microscopic study. J Mol Hist 2009;40:379-85.
10. Asad SA, Adnyana IK, Sigit JI. Minorthesis: Profil Penggunaan Jinten Hitam (Nigella sativa L.) untuk Terapi dan Pemeliharaan Kesehatan Masyarakat di Bandung dan Pekanbaru. Bandung: Institut Teknologi Bandung; 2012.
11. Gomori G. A differential stain for cell types in the pancreatic islets. Am J Pathol 1939;15 Suppl 4:497â€“9.
12. Ai J, Wang N, Yang M, Du ZM, Zhang, YC, Yang BF. Develompment of wistar rat model of insulin resistance. World J Gastroenteral 2005;11 Suppl 24:3675-9.
13. Levy J, Gavin III, JR, Fausto A, Gingerich RL, Avioli LV. Impaired Insulin Action in Rats with Non-insulin-dependent Diabetes. Diabetes 1984;33:901-6.
14. Etuk EU. Animal model for studying diabetes mellitus. Agric Biol J N Am 2010;1 Suppl 2:130-4.
15. Szkudelski T. The mechanism of alloxan and streptozotocin action in b cells of the rat pancreas. Physiol Res 2001;50 Suppl 6:537-46.
16. Andaloussi AB, Martineau L, Voung T, Meddah B, Madiraju P, Settaf A, et al. Reaserah article: the in vivo antidiabetic activity of nigella sativa is mediated through activation of the ampk pathway and increase muscle glut4 content. Evidance-Based Complementary Alternative Med 2011. p. 538-671.
17. Ahren B, Schmitz O. GLP-1 receptor agonists and dpp-4 inhibitors in the treatment of type 2 diabetes. Horm Metab Res 2004;36:867-76.
18. Thornberry NA, Gallwitz B. Mechanism of action of inhibitors of dipeptidyl-peptidase-4 (DPP-4). Best Pract Res Clin Endocrinol Metab 2009;23 Suppl 4:479-86.